Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

Springer eBooks

The Convergence of Quantum Computing and AI: Accelerating Next-Generation Therapeutic Discovery

Md Rahatul Ashakin

Published Jan 1, 2026• 0 citations
Publisher
DOI
10.1007/978-3-032-19536-4_3

Related papers

Quantum Informatics for Novel Therapeutics: AI-Enhanced Cybersecurity and Data Science for Next-Generation Healthcare

Don Roosan

Springer eBooks•Jan 1, 2026•0 citations

Multi-Platform Quantum Computing Simulation Pipeline for ADC Drug Design HER2-Trastuzumab Interface Analysis

Sungil Oh

Multi-Platform Quantum Computing Simulation Pipeline for ADC Drug Design: HER2–Trastuzumab Interface Analysis presents a quantum-classical hybrid framework for next-generation antibody-drug conjugate (ADC) discovery. This work integrates photonic quantum sampling, neutral-atom optimization, and variational quantum chemistry workflows with AI-assisted molecular design to analyze the HER2–Trastuzumab interface and generate optimized linker–conjugate candidates. The proposed pipeline addresses key limitations of conventional molecular dynamics (MD) and quantum mechanics (QM) simulations in large-scale protein interface analysis, introducing a scalable multi-platform quantum computing architecture for structure-based drug discovery. The study demonstrates a proof-of-concept workflow spanning target definition, quantum-derived residue prioritization, linker rule generation, conjugate assembly, docking validation, and downstream efficacy evaluation. Key highlights include:• 49 interface residues analyzed using photonic boson-sampling simulation• 162 conjugate candidates computationally generated and screened• Quantum-assisted ADC linker optimization workflow• HER2-targeted ADC feasibility validation using hybrid quantum-classical methods• Integration of AI, quantum computing, and molecular modeling for accelerated drug discovery This study represents an independent personal R&D initiative exploring the practical convergence of quantum computing and AI-driven pharmaceutical research, with applications in ADC design, automated protein preprocessing, and next-generation computational therapeutics.

•May 6, 2026•0 citations

Quantum Computing and Artificial Intelligence: A Convergence for Future Innovations

Fatma Foad Ashrif, Rami Ahmad, Faiza A. M. Mansour

Studies in computational intelligence•Jan 1, 2026•2 citations

Quantum Computing: A New Frontier in Drug Discovery

Adhira Tippur

•Jan 1, 2025•0 citations

Quantum Intelligence: The Convergence of AI and Quantum Computing

satish tukaram pokharkar, Suyog Sudam Medhe, Mohitkumar Gopinath Gaikwad +1 more

Quantum Intelligence: The Convergence of AI and Quantum Computing explores the transformative integration of Artificial Intelligence (AI) and quantum computing to address computational challenges beyond the capabilities of classical systems. The subject examines the fundamentals of quantum mechanics, quantum algorithms, and quantum machine learning, highlighting how quantum computing can accelerate data processing, optimization, pattern recognition, and complex decision-making.It covers key topics such as quantum neural networks, quantum-enhanced optimization, hybrid quantum-classical computing, cryptography, and AI-driven scientific discovery. The convergence of these technologies has the potential to revolutionize fields including healthcare, finance, cybersecurity, materials science, logistics, and climate modeling by solving problems with unprecedented speed and accuracy. By bridging the principles of AI and quantum computing, this field provides a foundation for next-generation intelligent systems, enabling groundbreaking innovations and shaping the future of computational intelligence.

•Jul 31, 2026•0 citations

A Next Generation Innovation in Drug Discovery Using Quantum Generative AI

Dr.C. Krishna Priya Dr.C. Krishna Priya, Nazeer Shaik, P. Chitralingappa

The convergence of Quantum Computing and Generative Artificial Intelligence (AI) marks a transformative leap in the field of drug discovery. Traditional drug development pipelines are often slow, costly, and limited by classical computational constraints. This paper presents a novel hybrid approach—QuantumGeneraDrug—that integrates quantum generative models with deep learning architectures to accelerate molecule generation, optimize binding affinities, and reduce computation time. A comprehensive literature survey highlights the evolution of both quantum algorithms and generative AI models applied to pharmaceutical research. The proposed system demonstrates improved performance over existing frameworks in key metrics such as valid molecule rate, druglikeness (QED) score, binding affinity accuracy, and processing time per compound. Comparative results are illustrated using numerical tables and visualized via bar and pie charts. The study concludes that Quantum Generative AI holds immense promise for next-generation drug discovery, especially in tackling complex diseases and enabling personalized medicine.

International Journal of Pharmaceutical Research and Applications•Apr 1, 2025•1 citation
Multi-Platform Quantum Computing Simulation Pipeline for ADC Drug Design: HER2–Trastuzumab Interface Analysis presents a quantum-classical hybrid framework for next-generation antibody-drug conjugate (ADC) discovery. This work integrates photonic quantum sampling, neutral-atom optimization, and variational quantum chemistry workflows with AI-assisted molecular design to analyze the HER2–Trastuzumab interface and generate optimized linker–conjugate candidates. The proposed pipeline addresses key limitations of conventional molecular dynamics (MD) and quantum mechanics (QM) simulations in large-scale protein interface analysis, introducing a scalable multi-platform quantum computing architecture for structure-based drug discovery. The study demonstrates a proof-of-concept workflow spanning target definition, quantum-derived residue prioritization, linker rule generation, conjugate assembly, docking validation, and downstream efficacy evaluation. Key highlights include:• 49 interface residues analyzed using photonic boson-sampling simulation• 162 conjugate candidates computationally generated and screened• Quantum-assisted ADC linker optimization workflow• HER2-targeted ADC feasibility validation using hybrid quantum-classical methods• Integration of AI, quantum computing, and molecular modeling for accelerated drug discovery This study represents an independent personal R&D initiative exploring the practical convergence of quantum computing and AI-driven pharmaceutical research, with applications in ADC design, automated protein preprocessing, and next-generation computational therapeutics.
Quantum Intelligence: The Convergence of AI and Quantum Computing explores the transformative integration of Artificial Intelligence (AI) and quantum computing to address computational challenges beyond the capabilities of classical systems. The subject examines the fundamentals of quantum mechanics, quantum algorithms, and quantum machine learning, highlighting how quantum computing can accelerate data processing, optimization, pattern recognition, and complex decision-making.It covers key topics such as quantum neural networks, quantum-enhanced optimization, hybrid quantum-classical computing, cryptography, and AI-driven scientific discovery. The convergence of these technologies has the potential to revolutionize fields including healthcare, finance, cybersecurity, materials science, logistics, and climate modeling by solving problems with unprecedented speed and accuracy. By bridging the principles of AI and quantum computing, this field provides a foundation for next-generation intelligent systems, enabling groundbreaking innovations and shaping the future of computational intelligence.
The convergence of Quantum Computing and Generative Artificial Intelligence (AI) marks a transformative leap in the field of drug discovery. Traditional drug development pipelines are often slow, costly, and limited by classical computational constraints. This paper presents a novel hybrid approach—QuantumGeneraDrug—that integrates quantum generative models with deep learning architectures to accelerate molecule generation, optimize binding affinities, and reduce computation time. A comprehensive literature survey highlights the evolution of both quantum algorithms and generative AI models applied to pharmaceutical research. The proposed system demonstrates improved performance over existing frameworks in key metrics such as valid molecule rate, druglikeness (QED) score, binding affinity accuracy, and processing time per compound. Comparative results are illustrated using numerical tables and visualized via bar and pie charts. The study concludes that Quantum Generative AI holds immense promise for next-generation drug discovery, especially in tackling complex diseases and enabling personalized medicine.